July 06, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
An online survey of 1,436 patients with rheumatic disease revealed “significant variability” in cannabis products used, efficacy and side effects, which were driven by several patient-specific factors, according to a study.“Our findings may provide guidance for clinicians and patients in the choice of cannabis products they use, given the wide range of marketed products in
July 06, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Although cannabis has been associated with psychosis, variations in studies driven by shifting policies have led to mixed…

For years, the relationship between cannabis smoking and lung cancer has been described as unclear or conflicting. Now, a large…

Patients with systemic autoimmune rheumatic disease demonstrate an increased persistence of SARS-CoV-2 antigen positivity up to 6…

How much cannabis is too much for the brain? The question is becoming more urgent as use rises and products become more potent.

Breaking news, emerging data, features and Q&As at the intersection of COVID-19 and rheumatology.

CHICAGO — Patients with autoimmune and rheumatic diseases who received antiviral therapy for COVID-19 demonstrated reduced…